Axitinib's Mechanism of Action in Metastatic Renal Cell Carcinoma Revealed

Scientists at Istanbul Technical University have conducted a comprehensive study on the interactions between Axitinib, a second-generation tyrosine kinase inhibitor, and DNA. Their research aimed to shed light on the pharmacodynamic properties of Axitinib and explore the possibility of developing more effective DNA-binding therapeutics. Through various analytical techniques, including UV-Vis spectroscopy, thermal denaturation assays, electrochemical methods, and fluorescence emission spectroscopy, the researchers gained valuable insights into the binding mechanism of Axitinib with DNA.

Key Takeaways:

• Axitinib binds to DNA through a groove binding mechanism, with a calculated binding constant (Kb) of (5.13 ± 0.28) x 10, indicating a potential for selective binding.
• Electrochemical studies revealed that Axitinib binds to the DNA minor groove, forming new hydrogen bonds with its functional groups and separating the guanine and cytosine base pairs.
• In-silico analyses using molecular docking and molecular dynamics simulations supported the groove binding mechanism, indicating that Axitinib selectively binds to the DNA minor groove through partial intercalation.
• The study's finding was confirmed by the research team's collaboration with Pelin Senel, Soykan Agar, Mine Yurtsever, and Aysegul Golcu from Istanbul Technical University.
• The Axitinib-DNA binding mechanism is crucial for understanding its pharmacodynamic properties and for the development of more effective DNA-binding therapeutics.
• The study provided new insights into the interaction between Axitinib and DNA, emphasizing the importance of further research in this area.

Statistics:

• Binding constant (Kb) for Axitinib-DNA interaction: (5.13 ± 0.28) x 10.
• Binding site for Axitinib on DNA: Minor groove.
• Hydrogen bonds formed between Axitinib and DNA: New hydrogen bonds with functional groups, separating guanine and cytosine base pairs.
• Molecular dynamics simulations: Partial intercalation between Axitinib and DNA.
• In-silico analyses: Supported the groove binding mechanism.

Sources:

• "Investigating the interactions of Axitinib, a tyrosine kinase inhibitor, with DNA: experimental studies, molecular docking, and molecular dynamics simulations." Nucleosides, Nucleotides & Nucleic Acids, 2025:1-24.
• Istanbul Technical University
• Taylor & Francis Inc., 530 Walnut Street, Ste 850, Philadelphia, PA 19106, USA (Publisher's contact information for Nucleosides, Nucleotides & Nucleic Acids)